SCHEDULE: Alta Partners Discloses 2.1% Stake in AEON Biopharma
Beneficial Ownership Report
Alta Partners LLC has reported a 2.1% beneficial ownership stake in AEON Biopharma, Inc., including shares from warrants, as detailed in its latest Schedule 13G amendment.
Summary
- Alta Partners LLC beneficially owns 249,870 shares of AEON Biopharma, Inc. common stock.
- This ownership represents 2.1% of the issuer's class of securities.
- The total beneficially owned shares include 15,500 shares issuable upon the exercise of warrants.
- Alta Partners LLC holds sole voting power and sole dispositive power over all 249,870 shares.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previous filing.
Sentiment
Score: 5
Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G) and does not contain information that inherently indicates positive or negative sentiment regarding the company's operational or financial performance. It is a factual report of an investment stake.
Future Outlook
NA
Management Comments
- Steven Cohen, Managing Member of Alta Partners LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.
Industry Context
This filing reflects a passive investment by Alta Partners LLC in AEON Biopharma, a company operating in the biopharmaceutical sector. Such disclosures are routine for institutional investors crossing certain ownership thresholds and typically do not indicate a shift in broader industry trends unless the stake is significantly larger or signals an activist position.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming a passive investment approach.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement |
| 10/14/2025 | Signature date of the Schedule 13G filing by Steven Cohen, Managing Member of Alta Partners LLC |
Keywords
AEON Biopharma, Alta Partners, Schedule 13G, beneficial ownership, common stock, biotech, investment, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.